< Back to previous page
Patent
Therapeutic agents for neurological and psychiatric disorders
The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPPĪ±) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPPĪ± with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
Patent Publication Number: US10829528
Year filing: 2020
Year approval: 2020
Year publication: 2020
Status: Assigned
URI: link to Espacenet
Technology domains: Analysis of biological materials, Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven